About 150 prescription drugs, including antibiotics, generics and some branded drugs without alternatives, could be at risk of shortage if the COVID-19 coronavirus outbreak worsens accordin
US biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the FDA agreed to a fast review in follicular lymphoma.
PharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for relapsed small cell lung cancer (SCLC).
